MultiVir withdraws IPO; RapidMist buccal delivery tech finds partner;

> Cancer gene therapy company MultiVir withdrew its $60 million IPO. More

> Generex is collaborating with NHTherapeutics. The companies will utilize Generex's RapidMist buccal delivery technology to deliver Leuprolide for the treatment of hypogonadism and other endocrine disorders. More